依达拉奉联合尤瑞克林治疗急性脑梗死疗效观察

摘要

Objective To investigate the clinical efficacy of edaravone combined with ureiklin in the treatment of acute cerebral infarction.Methods Seventy-two patients with acute cerebral infarction were enrolled in this study from July 2014 to October 2016 in Department of Neurology,the People's Hospital of Songxian.Patients were randomly divided into treatment group (n=36) treated with edaravone combined with irrecline;the control group (n =36) was treated with routine comprehensive therapy,and the clinical efficacy and neurological function were compared between the two groups.Results The total effective rate was 94.4％ in the treatment group and 77.8％ higher than that in the control group (P＜0.05).There was no significant difference in the NIHSS score between the treatment group and the control group (P＞0.0)5).After treatment,the NIHSS score of the treatment group was significantly lower than that of the control group (P ＜0.01).The average quality of life score was 90.1 ± 1.4 in the treatment group,which was higher than that in the control group (76.3 ± 4.7,P ＜0.01).Conclusion The clinical efficacy of edaravone combined with ureiklin in the treatment of acute cerebral infarction is effective and can improve its neurological function.%目的 探讨依达拉奉联合尤瑞克林治疗急性脑梗死的临床疗效.方法 在嵩县人民医院神经内科2014-07-2016-10诊治的急性脑梗死患者中抽取72例为研究对象,随机分为2组,治疗组(n=36)采取依达拉奉联合尤瑞克林治疗,对照组(n=36)应用常规综合治疗,对比2组临床疗效、神经功能变化.结果 治疗组总有效率94.4％,高于对照组的77.8％(P＜0.05);治疗前,2组NIHSS评分对比差异无统计学意义(P＞0.05);治疗后,治疗组NIHSS评分明显低于对照组(P＜0.01);治疗组生活质量评分(90.1±1.4)分,高于对照组的(76.3±4.7)分,差异有统计学意义(P＜0.01).结论 依达拉奉联合尤瑞克林治疗急性脑梗死的临床疗效确切,可有效改善其神经功能.